What are the recommended choices and dosing regimens for migraine prophylaxis in an adult patient?

Migraine Prophylaxis: Medication Choices and Dosing

For episodic migraine prophylaxis in nonpregnant adults, initiate monotherapy with either propranolol, metoprolol, topiramate, candesartan, or a CGRP monoclonal antibody (erenumab, fremanezumab, or galcanezumab), with the choice guided by comorbidities, cost, and patient preference. 1, 2

First-Line Medication Options

The 2025 American College of Physicians guideline provides the most current evidence-based framework for episodic migraine prevention (1-14 headache days per month) 1. The recommendations carry conditional strength with low-certainty evidence, but represent the best available guidance.

Beta-Blockers

• Propranolol: Strong evidence for efficacy, reduces migraine days by approximately 1.27 days per month 3

  • Typical dosing: 80-240 mg daily in divided doses
  • Preferred in patients with hypertension or anxiety

• Metoprolol: Equally well-supported 2, 4

  • Typical dosing: 50-200 mg daily

Angiotensin Receptor Blockers (ARBs)

• Candesartan: Strong recommendation (level A) 2

  • Typical dosing: 16-32 mg daily
  • Excellent choice for patients with hypertension

• Telmisartan: Also recommended 1

  • Typical dosing: 40-80 mg daily

Antiseizure Medications

• Topiramate: Reduces migraine days by approximately 1.4 days per month 3

  • Typical dosing: Start 25 mg daily, titrate to 50-100 mg twice daily
  • Caution: Teratogenic - avoid in women of childbearing potential without reliable contraception
  • Common side effects include cognitive slowing, paresthesias, weight loss

• Valproate: Weak recommendation for episodic migraine 2

  • Typical dosing: 500-1000 mg daily in divided doses
  • Contraindicated in pregnancy - highly teratogenic

CGRP-Targeted Therapies

Monoclonal Antibodies - Strong recommendation for both episodic and chronic migraine 2:

• Erenumab: 70 mg or 140 mg SC monthly, reduces migraine days by 1.0-2.5 per month 3
• Fremanezumab: 225 mg SC monthly or 675 mg SC quarterly, reduces migraine days by 1.3-3.8 per month 3
• Galcanezumab: 240 mg SC loading dose, then 120 mg monthly, reduces migraine days by 1.1-3.7 per month 3
• Eptinezumab: 100 mg IV quarterly (weak recommendation), reduces migraine days by 0.7-3.2 per month 2, 3

Gepants:

• Atogepant: Weak recommendation for episodic migraine 2
  • Dosing: 10 mg, 30 mg, or 60 mg daily orally
  • Reduces migraine days by 0.7-2.4 per month 3

Tricyclic Antidepressants

• Amitriptyline: Reduces migraine days by approximately 1.2 per month 3
  • Typical dosing: Start 10-25 mg at bedtime, titrate to 50-150 mg
  • Useful when comorbid insomnia or depression present
  • Side effects include sedation, dry mouth, weight gain

Algorithm for Medication Selection

Step 1: Assess Comorbidities

• Hypertension: Prioritize candesartan, telmisartan, propranolol, or metoprolol
• Depression/anxiety: Consider amitriptyline or propranolol
• Obesity: Consider topiramate (causes weight loss) or CGRP agents; avoid amitriptyline and valproate
• Insomnia: Consider amitriptyline
• Fibromyalgia: CGRP agents may be preferred 5

Step 2: Consider Reproductive Status

• Women of childbearing potential: Avoid valproate and topiramate unless using highly effective contraception
• Pregnancy: Most preventives are contraindicated; propranolol has most safety data 5
• Lactation: Limited data available; individualize risk-benefit 5

Step 3: Evaluate Prior Treatment Failures

• Multiple oral preventive failures: CGRP monoclonal antibodies are effective even after traditional oral agents fail 3
• Cost/access barriers: Traditional oral agents (propranolol, amitriptyline) are inexpensive generics

Step 4: Consider Tolerability Profile

• CGRP agents have superior tolerability with minimal side effects compared to traditional oral preventives 3, 6
• Constipation is the most common side effect of CGRP agents

Chronic Migraine (≥15 headache days/month)

For chronic migraine, additional options include:

• OnabotulinumtoxinA: Weak recommendation 2

  • Dosing: 155-195 units IM every 12 weeks across 31-39 injection sites
  • Specifically indicated for chronic migraine, NOT episodic migraine (weak recommendation against for episodic) 2

• CGRP monoclonal antibodies: Strong recommendation for chronic migraine 2

Important Clinical Considerations

Medication Overuse Headache Risk

Screen for high-risk factors before initiating prophylaxis 2:

• Headache frequency ≥7 days/month
• Frequent use of acute medications (analgesics, triptans, opioids)
• History of anxiety/depression
• Physical inactivity
• Tobacco use

Treatment Duration and Assessment

• Allow 2-3 months at therapeutic dose to assess efficacy 5
• Aim for ≥50% reduction in migraine frequency as treatment success
• If inadequate response after adequate trial, switch to alternative first-line agent 1

Agents with Insufficient Evidence or Not Recommended

• Insufficient evidence: Fluoxetine, venlafaxine, rimegepant, levetiracetam 1, 2
• Weak recommendation against: Gabapentin for episodic migraine 2
• Not recommended: SSRIs/SNRIs lack strong evidence 1

Common Pitfalls to Avoid

1. Inadequate dosing or duration: Many patients are undertreated with subtherapeutic doses or discontinued too early
2. Ignoring contraindications: Particularly valproate/topiramate in women of childbearing potential
3. Not addressing medication overuse: Prophylaxis is less effective with concurrent medication overuse headache
4. Polypharmacy without adequate monotherapy trials: Guidelines emphasize monotherapy first 1

The 2025 ACP guideline represents the most current authoritative source, though all recommendations carry conditional strength due to low-certainty evidence 1. The VA/DoD 2024 guideline provides complementary strong recommendations for specific agents like candesartan and CGRP monoclonal antibodies 2.